Skip to main content
. 2020 Apr 17;39(10):2919–2930. doi: 10.1007/s10067-020-05087-3

Fig. 2.

Fig. 2

Scenarios compared. BID, twice daily; csDMARD-IR, patients with an inadequate response or intolerance to previous therapy with a disease-modifying antirheumatic drug; MTX, methotrexate; sc, subcutaneous; TNFi-IR, patients with an inadequate response or intolerance to previous therapy with a tumour necrosis factor inhibitor